CABIO will remain committed to the research and production of HMOs, aiming to diversify their applications in the end market and provide a wider range of healthy choices for individuals across different age groups
CABIO unveiled an exciting new product range, NeoHMOs™, at the FIE 2023. CABIO team’s successful development and production of various physiologically active human milk oligosaccharides (HMOs) caters to the ever-increasing consumer demand for natural and high-quality products. By employing synthetic biology technology, we have implemented a rational design and control process for HMOs, effectively reducing greenhouse gas emissions and energy consumption during production, and ensuring an eco-friendly manufacturing process. Moving forward, CABIO will remain committed to the research and production of HMOs, aiming to diversify their applications in the end market and provide a wider range of healthy choices for individuals across different age groups, including infants and adults.
As a core supplier in the global infant formula supply chain, CABIO is committed to upholding its heartwarming corporate philosophy that “behind every can of formula lies a baby”, a value that has been cherished from the very beginning of our journey. We consistently maintain world-class standards in food safety and supply chain management, enabling us to provide high-quality functional nutritional products and diversified solutions to our customers in China and beyond.
At the FIE 2023, CABIO unveiled a wide range of products — arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc. as well as the NeoHMOs™ family, including 2′-Fucosyllactose (2′-FL), 3-Fucosyllactose (3′-FL), lacto-N-tetraose (LNT), lacto-N-neo-tetraose (LNnT), 3′-sialic lactose (3′-SL), and 6′-sialic lactose (6′-SL).
